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Summary
Surgery is the treatment of choice for symptomatic
primary hyperparathyroidism; unlikely few patients
do not meet established surgical criteria or have
comorbid conditions that prohibit surgery.
In these subjects, medical therapy alone offers little
hope for a sustained long normocalcemic period.
However percutaneous ethanol injection (PEI) may
represent an alternative therapeutic procedure. It is
currently in use for the treatment of secondary or
tertiary hyperparathyroidism, however, few studies
or case reports suggest it for the treatment of primary
hyperparathyroidism. Moreover, little information is
available about the long-term follow-up, where
incomplete necrosis or the spreading of ethanol in
the surrounding tissues is often reported. We believe
that many of the side effects could be correlated to
procedure itself. Taking these experiences into
account, we have reasoned that in order to limit
these side effects, we had to modify the standard PEI
procedure.
We reported this preliminary experience describing
our modified PEI procedure.
Introduction
Surgery is the treatment of choice for symptomatic
primary hyperparathyroidism1 except in rare cases
where the surgical approach is not suitable because
of technical difficulties and/or exceedingly high
anaesthesia risk.2,3 However, in these latter patients,
medical therapy alone offers little hope for a sus-
tained control of hypercalcemia.4 Percutaneous
treatment of a parathyroid adenoma by absolute
ethanol injection (PEI) may represent an alternative
therapeutic approach.5 This procedure was first
described by Solbiati and Colleagues in 19856 and
has been mainly used in the treatment of secondary
or tertiary hyperparathyroidism.7–15 A small number
of studies suggest that PEI may also be used for the
treatment of selected cases of primary hyperpara-
thyroidism,3,16–23 although incomplete inactivation
of the excessive parathormone (PTH) incretion or
spreading of ethanol in the surrounding tissues has
been reported;24 moreover, little information is
available concerning the long-term results of the
procedure. We present here the results of our
experience by using a modified PEI procedure in
the treatment of primary hyperparathyroidism,
including a follow-up up to 4 years.
Patients
First patient
A 68-year-old female was seen in our department in
March 2004 for hypercalcemia. Her past medical
history consisted of four episodes of neck surgery
treatments: the first was at the age of 14 years
for a brachial cyst; the second was thirty years
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later when she was submitted to a hemithyroid-
ectomy, followed by radical surgery for a follicular
thyroid carcinoma; then five years ago, at the age
of 63 years, the patient underwent surgical explora-
tion of the neck for hyperparathyroidism, but
no pathological parathyroid tissue was found; at
that time, a dual energy X-ray absorptiometry
(DEXA) of the spine and hip showed a significant
osteoporosis (T-score of 3.4). On admission, the
patient appeared to be suffering from osteoarthritis.
Laboratory investigation showed high levels of
alkaline phosphatase (242mU/ml, normal range
30–85), serum calcium (11.7mg/dl; normal range
8.5–9.5) and PTH (201pg/ml, normal range 12–72).
Neck ultrasound investigation (Figure 1) showed
an area of hypoechoic tissue (volume of 11.6ml),
suggestive of a parathyroid adenoma, while DEXA
(spine-hip) showed persistent signs of osteoporosis
(T-score of 3.58). Our surgeons, in consideration
of the repeated surgery to the neck, considered the
patient at high risk for recurrent laryngeal nerve
injury and overall surgery failure; consequently,
she refused further surgical treatment. We informed
the patient about the possibility of using PEI for
the treatment of the parathyroid adenoma and she
agreed, with a written consent.
Second patient
In July 2006, a 47-year-old female was admitted to
our department with hypercalcemia and pulmonary
embolism. She had been previously evaluated at
the Radiation Oncology unit, where she received
radiotherapy treatment following the resection of a
glioblastoma. Laboratory investigation showed high
levels of alkaline phosphatase (357mU/ml), serum
calcium (12.6mg/dl) and PTH (401 pg/ml). An
ultrasound examination showed the presence of
hypoechoic tissue in the left neck compartment,
suggestive of a parathyroid adenoma (volume of
14.8ml). Immunochemical PTH assay performed
on a parathyroid fine-needle aspiration biopsy
confirmed the diagnosis of primary hyperparathy-
roidism (PTH=93.000 pg/ml). Taking into account
the underlying clinical condition, we suggested that
the patient should be submitted to PEI, and she
agreed by signing written consent.
Methods
Ultrasound investigation was performed using an
ultrasonographic scanner (LOGIC 9, General
Electric, Milwaukee, WI, USA) equipped with a
10–14MHz linear transducer for morphological
study. The volume of the parathyroid was calculated
with the standard formula for ellipsoid volumes.
The PEI was performed with the patients in the
supine position. No topical anesthetics or sedatives
were used. The injection was made free hand, while
an experienced ultrasonographer guided the proce-
dure. We devised a modified two-step procedure.
The first step was intended to create a solid fibrosis,
visible at ultrasound as hyperechoic tissue, around
the capsule of the adenoma by using low ethanol
doses; to this purpose, after skin sterilization, a
25-gauge stylet needle was introduced into the
parathyroid adenoma and guided by real-time
ultrasound to the edge of the lesion; then, 0.5ml
of sterile 95% ethanol was introduced under the
capsule of the adenoma while monitoring the
Figure 1. Ultrasound investigation: hypoechoic tissue suggestive of parathyroid adenoma.
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diffusion of ethanol by ultrasound. After the needle
was withdrawn, each patient was observed for
10min. This procedure was first performed in the
posterior section of the adenoma and then repeated
several times (5–7) around the whole perimeter of
the lesion, at ten days intervals. The second step was
intended to introduce ethanol (80–85% of the
volume of the lesion) at the centre of the lesion, in
order to destroy the adenoma with a reduced risk of
alcohol spreading in the surrounding tissues.
Results
In order to obtain a visible hyperechoic ‘wall’
surrounding the adenoma, which would be
compatible with fibrosis (Figure 2), it was necessary
to repeat the first procedural step five times, at 10
days intervals. Two weeks after completing the
preliminary step, we injected ethanol (80–85% of
the calculated nodule volume) at the centre of the
adenoma. The first patient did not complain of any
pain or discomfort. One month thereafter, a calcium
replacement therapy was necessary for the treatment
of hungry bone syndrome. Neck ultrasound per-
formed after 36 months of follow-up did not show
any residual of the adenoma (Figure 3). Table 1
summarizes the laboratory findings before each
injection and during the follow-up. The patient
is currently (46 months after PEI) asymptomatic
for osteoarthritis and DEXA investigation of
Hyperechoic tissue
Figure 2. Ultrasound features after the first ‘step’: hyperechoic image all around the parathyroid adenoma.
Figure 3. Ultrasound after 20 months of follow-up.
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spine and hip shows a significant improvement in
T-score (1.9).
The same procedure was performed in the second
patient; in this case, seven alcohol injections were
necessary at the preliminary treatment step in order
to obtain a satisfying peripheral fibrosis of the
adenoma. Table 2 summarizes laboratory findings
before each injection and during the follow-up.
The patient deceased of relapsing glioblastoma
22 months after PEI; the last available measurement
of calcemia, 1 month before dying, was 8.4mg/dl.
Discussion
Primary hyperparathyroidism caused by a single
benign parathyroid adenoma is the most common
cause of chronic hypercalcemia3,25,26 and parathyr-
oidectomy represents the current treatment of
choice.3,25–28 In the few patients not suitable for
surgery, medical therapy alone offers little hope for
long-term normocalcemia,3,25–30 and thus far no
drug has been approved by the Food and Drug
Administration for the treatment of primary hyper-
parathyroidism.3 Therefore, in selected cases, PEI
could represent an alternative therapeutic proce-
dure. Indeed, PEI was introduced for the manage-
ment of parathyroid hyperplasia in the early 1980s,6
and many reports from that era describe its
use in secondary or tertiary hyperparathyroid-
ism.7,9,11,13,15,31 Recently, the Japanese Society for
Parathyroid Intervention has published PEI guide-
lines in chronic dialysis patients.1 On the other
hand, the role of percutaneous alcohol ablation in
the treatment of primary parathyroid adenomas is
not well established.3,16,17,19 Incomplete necrosis of
the adenomatous lesion has been reported24 and
little information is available about the long-term
results of this procedure; in addition, spreading of
ethanol to the surrounding tissues leading to the
development of extraglandular fibrosis that may
interfere with subsequent surgery has also been
described.5,17 Harman et al.19 reported that patients
treated by PEI for primary hyperparathyroidism and
followed over a 16-month period, redeveloped
hypercalcemia in 67% of cases and/or had recurrent
laryngeal nerve injury in 5.5%. More recently,
Karstrup et al.23 showed similar results.
Indeed, after reviewing data from the literature, it
appears that side effects are most likely related to the
amount of alcohol injected: in most cases a single
shot procedure with a large volume of ethanol was
performed.5,6,16,17 Taking these experiences into
account, we reasoned that in order to limit these
side effects, we had to modify the standard PEI
procedure. We aimed firstly to create a fibrotic wall
around the adenoma in order to avoid ethanol
spreading at a subsequent administration of a large
dose of ethanol; at the same time, the development
of perilesional fibrosis could possibly contribute
to reduce the vascularisation of the adenoma.
As reported here, repeated injections of small
doses of ethanol all around the adenoma were
able to induce an evident perilesional demarcation
(Figure 2) without modifying the PTH and calcium
serum levels of patients (Tables 1 and 2). The
number of micro-injections necessary to obtain the
Table 1 Laboratory findings before each injection and during follow-up (case 1)
I Step II Step Follow-up
18 28 38 48 58 1st month 45th month
Serum calcium (mg/dl) 10.4 9.9 10.3 10.1 10.4 10.3 8.0 8.9
Ionized calcium (mg/dl) 6.2 5.9 6.1 6.1 6.3 6.2 1.0 4.7
Intact PTH (pg/ml) 186 145 157 163 177 162 35 49
Table 2 Laboratory findings before each injection and during follow-up (case 2)
I Step II Step Follow-up
18 38 48 58 68 78 (17th month)
Serum calcium (mg/dl) 12.6 10.3 12.2 12.2 11.7 12.0 12.1 11.6 8.4
Ionized calcium (mg/dl) 7.2 6.2 7.0 7.0 6.9 7.0 6.9 6.0 4.5
Intact PTH (pg/ml) 401 162 393 363 405 374 359 362 42
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desired effect may vary in relation to the size of
the adenoma: five injections were sufficient in the
first patient presenting a lesion volume of 12ml,
whereas seven injections were performed in the
second case, carrying an adenoma of about 15ml.
Nevertheless, it is important to emphasize that the
patients did not complain of any pain or discomfort.
We have also shown that the injection of a high
ethanol volume at the subsequent step is well
tolerated and safe, a finding that is at some variance
with the experience reported by Karstrup et al.17
Finally, the validity of the modified PEI procedure
has been well documented by the persistent
normalization of PTH and calcium serum levels
through the longest follow-up period described thus
far and confirmed by the result of DEXA in the first
patient, showing a significant reduction of the
T-score over the time.
In conclusion we believe that our modified PEI
technique may be considered a suitable alternative
for the treatment of primary parathyroid adenoma
in selected patients, when the surgical approach is
not feasible or refused. Further investigation on a
larger series of patients is warranted to better assess
the overall efficacy and safety of the proposed
procedure.
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